Login
Manage Portfolio
Post a StockTalk
Write an Instablog
Get Daily Email Alert
Seeking Alpha
Home
The Macro View
Stocks & Sectors
Global Markets
ETFs
Investing Ideas
Breaking News
Transcripts
Business Intelligence
Introgen Therapeutics, Inc. (INGN)
(
)
Quotes
Dashboard
Chart
Historical Prices
Options
Analysis
Articles
Instablogs
StockTalks
Sentiment
Comments
News & PR
Market Currents
Buzz
Twitter: INGN
Coverage
Top Authors
Cramer
Top Analysts
Business Intelligence
Transcripts
Events
Key Developments
Earnings
History & Projected
Consensus
Peer Earnings
Filings
SEC Filings
Annual Report
Ownership
Major Holders
Insider Trades
Insider Sentiment
Index Membership
Short Interest
Financials
Income Statement
Balance Sheet
Cash Flow
Company
Wikipedia Profile
Officers & Directors
Executive Comp
52wk high:
52wk low:
EPS:
PE:
Dividend:
Yield:
Market Cap:
Exchange:
Analysis - Latest Articles
Failure to Launch for Last Year's Big Pharma and Biotech Hopes
EP Vantage
•
Feb 13
•
Comment!
FDA Calendar: Cardiome, Momenta, Discovery Labs, Introgen
Mike Havrilla
•
Aug 07
•
2 Comments
Introgen Therapeutics: Advexin's P-Value Borg - Resistance is Futile
The Biotech Onion
•
Jun 04
•
6 Comments
Cancer Stocks: Tracking the Market
Alan Brochstein
•
Jul 09
•
Comment!
Introgen Hints At Cancer Gene Therapy Lawsuit Against Benda
ChinaBio Today
•
Jul 06
•
Comment!
Cancer Stocks Slide Again
Alan Brochstein
•
Jun 18
•
1 Comment
More articles on INGN »
Sentiment
What advice would you give to
INGN?
123 characters left
What's your view of INGN?
Make sure you include INGN
140 characters left
|
Settings